xylonix
Xylonix is a Singapore-based pharmaceutical company that develops macrophage-targeted therapeutics (C010DS-Zn) and consumer health products (Hygiene Nasal Spray, DIGESTIX) for cancer, Long COVID, and immune dysfunction, distributed via its website and a 100+ clinic network across Singapore, Korea, the Philippines, the US, and Australia.
- Company typePrivate
- Founded-
- HeadquartersSingapore, Singapore
- Headcount—
- GTM typeB2C
- OfferingHardware or Manufacturing
What xylonix does
Xylonix PTE. LTD. is a Singapore-incorporated, privately held pharmaceutical company founded and led by Dr. Jinhyuk Fred Chung that develops macrophage-targeted therapeutics and consumer health products. The company's scientific premise is that dysfunctional macrophages drive cancer immune evasion, metastasis, and post-COVID syndromes including Long COVID; it operationalizes this thesis through three product lines. The lead pharmaceutical asset, C010DS-Zn, is a parthanatos-inducing zinc oncology agent developed with Duke-NUS Medical School that targets M2-like tumor-associated macrophages. The commercial consumer health portfolio includes a Hygiene Nasal Spray built on 0.05% Povidone-Iodine and DIGESTIX, a patent-pending blend of activated charcoal, coffee bean fiber, and honey aimed at reducing gut-derived IL-6. The business model combines direct-to-consumer e-commerce (xylonix.io) with clinic and pharmacy distribution across Singapore (100+ clinics), Korea, the Philippines, the US, and Australia, supplemented by diagnostic distribution rights for Invitrocue's Onco-PDO and ADPS platforms in Korea and Japan.
The company monetizes primarily through one-time purchases of low-priced consumer SKUs ($45 nasal spray packs and $140 DIGESTIX 60-sachet boxes as of), freemium trials (DIGESTIX 15-sachet free trial with paid shipping), and emerging licensing/distribution economics from Korean and Japanese cancer diagnostic partnerships. Go-to-market combines content-led acquisition (scientific blog and peer-reviewed publications) with channel partner distribution in clinical and pharmacy networks. R&D direction has been progressively broadened through strategic alliances: Genecast for ADPS-PCR cancer diagnostics, Invitrocue for Onco-PDO and ADPS, EukairosCell for a Korean IVD lab, and LysinBio for antibacterial Disease X preparedness, alongside a Duke-NUS immunotherapy collaboration dating to October 2021. No external venture, private equity, or strategic investor participation is disclosed, leaving Xylonix founder-controlled and privately financed.
xylonix firmographics
Firmographics- Name
- xylonix
- Legal name
- Xylonix PTE. LTD.
- Website
- https://xylonix.io
- Company type
- Private
- Operating status
- Operating
- Short description
- Xylonix is a Singapore-based pharmaceutical company that develops macrophage-targeted therapeutics (C010DS-Zn) and consumer health products (Hygiene Nasal Spray, DIGESTIX) for cancer, Long COVID, and immune dysfunction, distributed via its website and a 100+ clinic network across Singapore, Korea, the Philippines, the US, and Australia.
- Ownership category
- akta.pro rank
xylonix industry classification
Industry- Product category
- Pharmaceutical and Consumer Health Products
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
Keywords
Where xylonix is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices1 record
Markets served
xylonix business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
Revenue model
- Consumer Health Products: Sale of direct-to-consumer health products including Hygiene Nasal Spray (PVD-Iodine antiseptic) and DIGESTIX (gut health supplement) through e-commerce and clinic/pharmacy distribution channels.
- Pharmaceutical Development: Development of novel oncology and immunology drugs including C010DS-Zn for cancer treatment, with potential future licensing or co-development revenues through partnerships.
- Distribution Rights: Securing exclusive distribution rights for partner products (e.g., Invitrocue's Onco-PDO and ADPS cancer diagnostics) in Korea and Japan.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | DIGESTIX 60 sachets (1-month supply) |
| Freemium | Pay-as-you-go | DIGESTIX 1-week free trial (15 sachets) |
| One time/ perpetual license | Pay-as-you-go | Hygiene Nasal Spray 4 bottles (4x30mL) |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
xylonix product offering
Product offeringCore offering
Xylonix develops pharmaceutical and consumer health products targeting dysfunctional macrophages that drive cancer immune evasion, Long COVID, and post-pandemic immune disorders. Its commercial product line consists of Hygiene Nasal Spray (PVD-Iodine antiseptic for nasal hygiene) and DIGESTIX (patent-pending gut-derived IL6 reduction supplement), with the C010DS-Zn oncology agent in research and development in collaboration with Duke-NUS Medical School.
Product overview
Xylonix is a pharmaceutical company dedicated to developing innovative treatments for disorders driven by dysfunctional macrophages, including cancer, Long COVID, and infectious diseases. The product portfolio consists of two consumer health products: Hygiene Nasal Spray (0.05% Povidone-Iodine antiseptic for nasal hygiene and respiratory defense) and Digestix (a patent-pending dietary supplement targeting gut-derived IL6 through endotoxin reduction). Additionally, Xylonix is developing C010DS-Zn, an oncology agent targeting cancer-associated macrophages, in collaboration with Duke-NUS Medical School. The company also has strategic partnerships for cancer diagnostics distribution (with Genecast for ADPS technology and Invitrocue for Onco-PDO) but these are commercial partnerships rather than technical product integrations.
Differentiator
Problem solved
Functional benefit
Products and services
- Hygiene Nasal Spray Topical antiseptic nasal spray formulated with 0.05% Povidone-Iodine (PVD-Iodine) for reducing the spread of germs and viruses in the nasal cavity. Designed for frequent ongoing use to reduce risks of upper respiratory infections and promote nasal health, including rhinitis and allergy management. Sold online to consumers in Australia, Singapore, and the US, and distributed through Korean pharmacies and clinics in a drug-free variant.
- DIGESTIX Patent-pending dietary supplement targeting gut-derived IL6 for potential Long COVID relief through endotoxin reduction. Contains activated charcoal, coffee bean fiber, and honey to reduce fecal bacterial load and endotoxemia. Sold as a 60-sachet one-month supply for $140 USD with free shipping, available in Australia and Singapore.
- C010DS-Zn Oncology agent (PARP1 agonist) targeting cancer and M2-like macrophages through parthanatos pathway induction. Elicits anti-tumor immune responses involving T cells and macrophages in vivo. Developed in collaboration with Duke-NUS Medical School for treating both cancer and complications arising from COVID-19 infection. Not currently sold as a commercial product; IP is filed-pending.
Quantifiable outcome
- 115% highest risk increase in certain cancers within 3 months of COVID-19 infection
- +2 more outcomes
Companies that use xylonix
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
xylonix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
xylonix partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- InvitrocuecoreStrategic clinical alliance to validate new methods for combating IL-6 pathologies common in cancer, autoimmune conditions, and Long COVID. Partnership addresses a critical gap in management of IL-6 driven diseases.
- EukairosCellcoreMOU signed with EukairosCell, Invitrocue, and Genecast to launch Korea's first IVD lab for advanced cancer treatment diagnostics. Collaboration brings together cutting-edge diagnostic technologies for real-time cancer tracking and personalized treatment solutions.
- Invitrocue (Distribution Rights)coreXylonix secured exclusive distribution rights for Invitrocue's Onco-PDO and ADPS cancer diagnostics in Korea and Japan. Partnership delivers Real-Time Cancer Adaptive Program to cancer patients across both countries.
- LysinBiominorPartnership to combat Disease X of bacterial origin, focusing beyond viruses to prepare for deadlier bacterial Disease X with super antibacterials and nasal sprays.
- GenecastcoreStrategic partnership to advance early precision cancer diagnostics and cancer metastasis research. Leverages Genecast's cutting-edge ADPS-PCR technology for ultra-sensitive detection of oncogene mutations (0.01% MAF sensitivity). Xylonix provides research advisory, scientific marketing, and expands reach through established sales networks.
- Duke-NUScoreCollaboration with Duke-NUS Medical School to improve effectiveness of Xylonix cancer drugs. New drug formulations aim to improve in vivo circulation of novel immunotherapies for treating both cancer and complications arising from COVID-19 infection.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
xylonix competitors and assessment
Company assessmentDirect peers
- Carisma Therapeutics: Clinical-stage biotech engineering macrophage and monocyte cell therapies for cancer and inflammatory diseases. Directly comparable as a macrophage-focused oncology platform pursuing similar reprogramming-based mechanisms.
- Macomics: UK-based macrophage biology drug discovery company developing therapeutics targeting tumor-associated macrophages. Comparable as a dedicated macrophage-targeting oncology platform.
- Pionyr Immunotherapeutics: Clinical-stage biotech developing myeloid-based immunotherapies targeting the tumor microenvironment. Highly comparable given shared focus on myeloid/macrophage reprogramming in oncology.
- Equillium: Clinical-stage immunology company developing IL-6 pathway-targeting therapies for autoimmune and inflammatory diseases. Directly comparable given shared IL-6 cytokine focus and Long COVID/autoimmune positioning.
- Invitrocue: Singapore-based oncology diagnostics company whose Onco-PDO and ADPS products Xylonix distributes exclusively in Korea and Japan. Comparable as both a diagnostics partner and Asian oncology-focused entity.
- Myeloid Therapeutics: Clinical-stage biotech developing myeloid cell therapies and immuno-oncology approaches. Comparable as a macrophage/myeloid cell-focused oncology platform pursuing similar reprogramming strategies.
- Xlear: Consumer health company marketing xylitol-based nasal hygiene sprays for sinus and respiratory health. Comparable as a nasal hygiene consumer health product competing in a similar over-the-counter category.
Broad incumbents
- Vir Biotechnology: Clinical-stage immunology company addressing infectious diseases including COVID-19 and Long COVID. Comparable as a well-capitalized immunology platform addressing COVID-endemic health challenges.
- Guardant Health: Leading precision oncology company offering liquid biopsy and advanced cancer diagnostics. Comparable given Xylonix's cancer diagnostics distribution ambitions in Asia and overlap in the precision oncology space.
Emerging players
- Seed Health: Microbiome-focused consumer health and clinical-stage company developing gut-microbiome-based interventions. Comparable as a science-driven consumer health company targeting gut-derived inflammation pathways.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
xylonix social profiles
Digital presencexylonix financial estimates
Financial estimateRevenue estimate
Valuation estimate
xylonix leadership team
Management profileNumber of profiles
Profiles1 record
xylonix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
xylonix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about xylonix
What does xylonix do?
Xylonix develops pharmaceutical and consumer health products targeting dysfunctional macrophages that drive cancer immune evasion, Long COVID, and post-pandemic immune disorders. Its commercial product line consists of Hygiene Nasal Spray (PVD-Iodine antiseptic for nasal hygiene) and DIGESTIX (patent-pending gut-derived IL6 reduction supplement), with the C010DS-Zn oncology agent in research and development in collaboration with Duke-NUS Medical School.
Is xylonix a public or private company?
xylonix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was xylonix founded?
xylonix was founded in -1.
Where is xylonix based?
xylonix is headquartered in Singapore, Singapore, in the Asia region.
How does xylonix make money?
Three revenue lines are on record. Consumer Health Products are the primary driver. The others are pharmaceutical Development and distribution Rights.
Who are xylonix's main competitors?
Direct peers on record are Carisma Therapeutics, Macomics, Pionyr Immunotherapeutics, Equillium, Invitrocue, Myeloid Therapeutics and Xlear. Broad incumbents are Vir Biotechnology and Guardant Health. Seed Health is listed as an emerging player.
Does xylonix have an API?
No public API is recorded for xylonix.
What industry is xylonix in?
xylonix's product category is Pharmaceutical and Consumer Health Products. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.